Fairvalue-Calculator Fairvalue-Calculator
EN DE

Vcanbio Cell & Gene Engineering Corp (600645) Fair Value & Analysis

Healthcare · CN · Market cap 8.8B CNY

Price¥17.99
Fair Value¥8.57
Upside-52.4%
Quality94/100
Evidence: High Range ¥6.93 – ¥10.21

Analysis

Vcanbio Cell & Gene Engineering Corp (600645) currently trades at ¥17.99, while our model-based Fair Value estimate is ¥8.57 — implying the stock looks roughly 52.4% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental stem cells. The company also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug safety guidance, disease genetic testing, and disease susceptibility testing for children and adults; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products. In addition, it is involved in the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and synthetic agents; and in vitro diagnostic reagents and medical devices. The company …

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.